Faeth Therapeutics, Inc.

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth Therapeutics granted three new employees options to purchase an aggregate of 17,000 shares as employment inducement awards under Nasdaq Listing Rule 5635(c)(4). The options carry a $19.44 exercise price equal to the grant-date closing price, with standard four-year vesting (25% after one year, then 36 monthly installments) and a ten-year term. The disclosure is routine compensation boilerplate with no bearing on the company's clinical programs or financials.

•3d ago

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

Faeth Therapeutics will present preclinical data on PIKTOR in HR+/HER2- breast cancer models at the ESMO Congress 2026, with the poster scheduled for October 23 in Madrid. The poster characterizes PIKTOR as monotherapy and in combination with fulvestrant, oral SERDs, and CDK inhibitors, and includes head-to-head xenograft comparisons with gedatolisib, another multi-nodal PI3K-AKT-mTOR pathway inhibitor. The data are intended to inform the ongoing FTH-PIK-101 Phase 1b/2 breast cancer trial (first patient dosed April 2026, interim data expected 2027), while the Phase 2 endometrial cancer trial FTH-PIK-201 is expected to read out topline data by year-end 2026.

•6d ago

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

Faeth Therapeutics will host a virtual key opinion leader event on October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD of NYU Langone Health, to discuss the PI3K/AKT/mTOR (PAM) pathway and the company's upcoming Phase 2 readout in endometrial cancer. PIKTOR, the lead program, is an investigational all-oral combination of the PI3K-alpha inhibitor serabelisib and the mTORC1/mTORC2 inhibitor sapanisertib, currently in a Phase 2 trial (FTH-PIK-201) in second-line advanced endometrial cancer with topline data anticipated by year-end 2026. The release notes approximately 80% of endometrial tumors harbor a PAM pathway alteration and treatment options after checkpoint inhibitor therapy remain limited. PIKTOR is also in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer, where the first patient was dosed in April and interim data is anticipated in 2027. No new clinical data was disclosed; this is an investor-education and catalyst-calendar item ahead of the year-end readout.

•1mo ago

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

Faeth Therapeutics announced that management will participate in six investor conferences throughout September 2026, including events hosted by Wells Fargo, Citi, and Morgan Stanley. The schedule features fireside chats at the Citi Biopharma Back to School Summit, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference, along with 1x1 meetings at the Wells Fargo and Deutsche Bank events. Live webcasts for the Cantor and Morgan Stanley fireside chats will be available on the Faeth website, with replays accessible for 90 days following the events. The company is a clinical-stage oncology firm focused on its lead program PIKTOR, an investigational combination therapy for endometrial and breast cancer.

•1mo ago

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth Therapeutics granted inducement options to purchase an aggregate of 94,000 shares of common stock to three new employees effective August 25, 2026. The options have an exercise price of $34.52 per share, equal to the closing price on the grant date, and vest over four years with a one-year cliff. The company is a clinical-stage biotechnology firm focused on its lead program PIKTOR for endometrial and breast cancer.

•1mo ago

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth Therapeutics granted options to purchase an aggregate of 11,000 shares of common stock to two new employees as a material inducement to employment. The options have an exercise price of $25.50 per share, equal to the closing price on the grant date, and will vest over a four-year period. Faeth is a clinical-stage biotechnology company focused on oncology, with its lead program PIKTOR currently in development for endometrial and breast cancer.

•2mo ago

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

Faeth Therapeutics reported Q2 2026 net loss of $16.0 million, or $2.84 per share, with cash and equivalents increasing to $186.4 million from $21.2 million at year-end 2025. The strengthened balance sheet supports the development of PIKTOR, with topline data from the Phase 2 endometrial cancer trial on track for year-end and the first patient dosed in a Phase 1b/2 HR+ breast cancer trial in April. Corporate updates include the official name change to Faeth Therapeutics, trading under ticker FTH, the appointment of Anand Parikh as CEO, and the addition of former FDA Commissioner Stephen M. Hahn to the board.

•2mo ago

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth Therapeutics granted options to purchase 25,500 shares of common stock to two new employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $28.19 per share, which was equal to the closing price on the grant date of July 20, 2026. Vesting will commence with 25% on the first anniversary of each employee's start date, followed by monthly vesting over 36 months.

•3mo ago

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth Therapeutics granted options to purchase an aggregate of 180,350 shares to six new employees as a material inducement to employment under Nasdaq Rule 5635(c)(4). The grants were split between two dates, with 157,850 shares granted on June 25 at an exercise price of $24.67 and 22,500 shares granted on June 29 at an exercise price of $23.22. The options vest with 25% on the first anniversary of employment, followed by 36 equal monthly installments, subject to continued service.

•3mo ago